“The actions outlined today will better position us to drive meaningful earnings growth and further strengthen the company to ...

Precision Neuroscience’s brain-computer interface—a wireless device that aims to restore function to people with paralysis—is ...

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

After a three-month delay, the FDA has now rejected an approval request based on the RWE. According to Biohaven, the FDA’s complete response letter “cited issues that can be inherent to real-world ...

In response to the stronger-than-expected quarter, GE HealthCare adjusted its 2025 earnings per share profit forecast to ...

Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as ...